Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion type Assertion NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_head.
- NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion description "[PLTP activity and apoE were measured in patients with type 2 diabetes from the DALI (Diabetes Atorvastatin Lipid Intervention) Study, a 30-week randomized double-blind placebo-controlled trial with atorvastatin (10 and 80 mg daily).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_provenance.
- NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion evidence source_evidence_literature NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_provenance.
- NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion SIO_000772 16644710 NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_provenance.
- NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion wasDerivedFrom befree-20150227 NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_provenance.
- NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_assertion wasGeneratedBy ECO_0000203 NP631602.RAGPf2sz2t61i6FjMQ9MKccH2SrZyDVV-QFd9x_JCT-LM130_provenance.